サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1781927

非小細胞肺がん治療市場：療法別、流通チャネル別、がんタイプ別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測

Non-Small Cell Lung Cancer Therapeutics Market, By Therapy, By Distribution Channel, By Cancer Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 288 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.67円
非小細胞肺がん治療市場：療法別、流通チャネル別、がんタイプ別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

非小細胞肺がん治療市場規模は2024年に214億6,120万米ドルとなり、2025～2032年にかけてCAGR 12.99%で拡大

非小細胞肺がん治療市場-市場力学

非小細胞肺がん治療市場は、執拗な喫煙パターンと環境汚染の増加による肺がん罹患率の世界の上昇によって牽引され、効率的な治療の必要性を高めています。世界保健機関（WHO）によると、肺がんは世界的に主要ながんキラーです。さらに、NSCLCの分子基盤の解明における急速な進歩は、より正確で毒性の少ない可能性のある治療を約束する標的療法や免疫療法を生み出す理論的根拠への道を開いた。新たなバイオマーカーや治療標的の研究がさらに進めば、より個別化された治療法の確立が期待されます。免疫療法と標的治療の併用は、特に進行した疾患において、患者の予後を改善する有望な結果をもたらします。

さらに、早期治療に対する反応を同定・追跡するためのリキッドバイオプシーなどの高度診断の利用が拡大しており、より早期で効果的な治療が可能となっています。ヘルスケアインフラの成長と、新興市場における先進的がん治療への注目の高まりも、大きな成長機会となります。しかし、いくつかの新しい治療法、特に標的療法や免疫療法の高価格は、世界中の患者集団のかなりの割合にとって大きなアクセス障壁となっています。また、複雑な規制環境と長引く新製品の承認プロセスも、市場拡大の足かせとなっています。

非小細胞肺がん治療市場-主要な洞察

標的治療は、NSCLCの特定の分子サブタイプ、特に最も一般的な組織型である腺がんの治療に非常に有効であるため、大きな市場シェアを有しています。EGFR、ALK、その他の作用性変異を標的とした薬剤の成功により、標的療法はNSCLC治療の主軸となり、これらの変異を有するほとんどの患者で無増悪生存期間が延長されました。

免疫療法は予測期間中に最も急速に拡大します。これは、進行した病期であっても、一定の割合の患者において持続的な奏効と長期的な生存利益をもたらすことができるためです。免疫チェックポイント阻害剤は、単独療法、化学療法や標的療法との併用療法ともに、NSCLCのさまざまなサブタイプや病期で適応が拡大していることが、この拡大に拍車をかけています。

オンライン薬局は最も急速に成長している流通チャネルであると予測されます。この成長の原動力となっているのは、オンラインチャネルが提供する利便性、アクセス性、時には費用対効果の向上です。遠隔医療や遠隔ケアサービスの採用増加も、経口NSCLC治療の流通におけるオンライン薬局の成長を後押ししています。

腺がんはNSCLCの組織学的サブタイプとして世界で最も普及しており、現在利用可能な治療法で標的とできる特定の遺伝子変異を示すことが多いため、最大の市場シェアを占めています。その有病率の高さと利用可能な標的療法により、治療市場の主要参入企業となっています。

非小細胞肺がん治療市場-セグメンテーション分析

世界の非小細胞肺がん治療市場は、治療法、流通チャネル、がんタイプ、地域に基づいてサブセグメンテーションされます。

治療法別では、標的療法、免疫療法、化学療法に区分されます。標的療法は市場で最も大きなシェアを占めています。この優位性は、NSCLCの分子的背景の解明が飛躍的に進んだ結果、EGFR、ALK、ROS1、BRAFのような特定の発がんドライバーの同定が可能になったことに起因します。これらの変異を標的とする薬剤が開発され、承認されたことで、特に腺がんにおいて、このような変異を有する患者の治療モデルは大きく変化しました。標的薬剤は一般に、これらの特定の患者群において従来型化学療法よりも高い有効性と良好な毒性プロファイルを示し、それゆえ初回とフォローアップ治療プロトコールの重要な要素となっています。免疫療法は市場で最も急成長しているセグメントです。この急成長の原動力は、免疫チェックポイント阻害剤による画期的な効果であり、さまざまなサブタイプのNSCLC患者の一部で、持続的な奏効と長期生存をもたらす能力が証明されています。免疫療法の適応を疾患の早期段階にまで広げ、化学療法や標的療法などの他の治療法と組み合わせることが、市場の成長をさらに後押ししています。

市場は流通チャネル別に、病院薬局、小売薬局、オンライン薬局、その他に区分されます。病院薬局は市場最大のセグメントです。NSCLCの治療には、化学療法や免疫療法のような複雑な点滴治療が頻繁に行われるため、このセグメントが最大の市場シェアを占めています。ヘルスケアは、これらの治療を安全に実施・モニタリングするために、専門の輸液センターや熟練した医療専門家など、必要なインフラを備えています。加えて、病院の薬局は、入院中に配合される薬剤や、専門のがんセンターで治療を受ける外来患者のための最初の調剤場所となることがほとんどです。オンライン薬局は、市場で最も急速に拡大しているセグメントです。eコマースの普及と、オンラインウェブサイトが提供する利便性の向上が、この拡大の背景にあります。オンライン薬局は、標的治療や特定の支持療法薬を含め、NSCLCの治療に使用される経口薬へのアクセスを患者に便利にしています。オンラインドラッグストアは競合価格や宅配便の利便性を持つ傾向があり、肺がんのような進行中の疾患を持つ患者には特に有用です。

非小細胞肺がん治療市場-地理的洞察

北米は非小細胞肺がん治療の最大の地域市場です。その背景には、整備されたヘルスケアインフラ、高い医療費、大手製薬企業による新薬のイノベーションと早期導入といった要因があります。米国は肺がんの罹患率が最も高い国のひとつであり、新薬の迅速な承認・採用を可能にする効果的な規制インフラが整備されています。さらに、研究開発への重点的な取り組みと積極的な償還施策が、北米のリーダーシップに拍車をかけています。アジア太平洋のは、非小細胞肺がん治療で最も急速な成長を遂げています。この急成長は、中国やインドなどの市場における膨大かつ増加する患者ベース、喫煙や大気汚染の発生率の増加、医療へのアクセスや価格の向上によるところが大きいです。ヘルスケアインフラへの支出が増え続けていること、免疫療法や標的療法などの先進的がん治療の利用率が高まっていることも、大きな成長促進要因となっています。さらに、臨床検査数の増加や地元製薬企業の開発が、この地域の急成長を後押ししています。

非小細胞肺がん治療市場-競合情勢

非小細胞肺がん治療市場は、多くの既存製薬企業やバイオテクノロジー企業、新規参入企業による競争の激しい市場です。ジェネンテック（F.ホフマン・ラ・ロシュ社）、イーライリリー・アンド・カンパニー、AstraZeneca、Pfizer、ブリストル・マイヤーズ・スクイブ、Merck・シャープ・アンド・ドーム社などの市場は、承認された治療の幅広いポートフォリオ、研究開発力、確立された世界的流通チャネルを兵器に、大きなシェアを占めています。これらの企業は、NSCLC患者の進化するニーズに対応し、治療に対する耐性を克服するために、新しい標的療法、免疫療法、併用療法を開発しています。また、戦略的提携、ライセンシング契約、買収により、製品パイプラインと市場カバレッジを拡大するための競争も激化しています。イノベーションは差別化要因のひとつであり、各社は新たな治療標的の同定、次世代阻害剤、抗体薬剤複合体や細胞療法などの新規治療アプローチを対象としています。個別化医療やバイオマーカーによる治療アプローチへの注目の高まりも競合を生み出しており、各社はコンパニオン診断に投資し、自社の治療が最も奏効しやすい患者サブセットを決定しています。

目次

第1章 非小細胞肺がん治療市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 非小細胞肺がん治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 非小細胞肺がん治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 非小細胞肺がん治療市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 非小細胞肺がん治療市場情勢

  • 非小細胞肺がん治療市場シェア分析（2024年）
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 非小細胞肺がん治療市場-療法別

  • 概要
    • 療法別セグメントシェア分析
    • 標的療法
    • 免疫療法
    • 化学療法

第8章 非小細胞肺がん治療市場-流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第9章 非小細胞肺がん治療市場-がんタイプ別

  • 概要
    • がんタイプ別セグメントシェア分析
    • 腺がん
    • 扁平上皮がん
    • 大細胞がん

第10章 非小細胞肺がん治療市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析-非小細胞肺がん治療産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
    • Eli Lilly and Company
    • Celgene Corporation
    • AstraZeneca
    • Pfizer Inc.
    • Sanofi
    • Novartis AG
    • Astellas
    • Bristol Myers Squibb
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Millennium Pharmaceuticals, Inc.（Takeda）
    • Merck Sharp & Dohme Corp.

第12章 アナリストの全方位的展望

目次
Product Code: ANV5369

REPORT HIGHLIGHT

Non-Small Cell Lung Cancer Therapeutics Market size was valued at US$ 21,461.20 Million in 2024, expanding at a CAGR of 12.99% from 2025 to 2032.

Non-small cell lung cancer (NSCLC) therapeutics include a wide range of pharmacological and interventional interventions used in the treatment of lung cancers that do not qualify as small cell lung cancer. The therapeutic regimen for NSCLC has come a long way, going beyond the conventional use of chemotherapy to include targeted therapies that take advantage of specific tumour cell genetic mutations and immunotherapies that use the body's immunity against cancer. These therapies suppress cancer cell proliferation, trigger apoptosis (programmed cell death), and suppress metastasis. A therapeutic approach is selected based on factors such as the histological subtype of NSCLC, the stage of cancer at the time of diagnosis, the presence of specific biomarkers, and the patient's health status. The goal of therapy for NSCLC is to prolong survival, improve the quality of life, and palliate symptoms due to disease.

Non-Small Cell Lung Cancer Therapeutics Market- Market Dynamics

The market for non-small cell lung cancer therapeutics is driven by the propelling global incidence of lung cancer due to relentless smoking patterns and rising environmental pollution, which drives the need for efficient treatments. Lung cancer is a major cancer killer globally, according to the World Health Organization. Moreover, the rapid advances in unraveling the molecular underpinnings of NSCLC have opened the way for the rationale of creating targeted therapies and immunotherapies that promise more precise and potentially less toxic treatment. Further investigations into new biomarkers and targets for therapy have the promise to create more personalized medicine modalities. Combining immunotherapy with targeted agents yields encouraging results that enhance patient outcomes, especially in advanced disease.

In addition, the growing use of advanced diagnosis, such as liquid biopsies to identify and track response to early treatment, enables earlier and more effective treatments. The growth in healthcare infrastructure and the rising exposure to sophisticated cancer treatment in emerging markets also offer significant growth opportunities. However, the high price of several new therapies, especially targeted and immunotherapies, is a huge access barrier for a substantial share of the patient population worldwide. The complicated regulatory environment and the long, drawn-out approval process for new products can also hold back market expansion.

Non-Small Cell Lung Cancer Therapeutics Market- Key Insights

Targeted therapy has a substantial market share because it is highly effective in treating specific molecular subtypes of NSCLC, especially adenocarcinoma, the most common histologic subtype. Success with EGFR, ALK, and other actionable mutation-targeted drugs has made targeted therapy a mainstay of NSCLC therapy, resulting in enhanced progression-free survival in most patients with these alterations.

Immunotherapy is witnessing the most rapid expansion during the forecast period. This can be ascribed to its capability to yield durable responses and long-term survival benefits in a proportion of patients, even in advanced disease stages. Growing indications for immune checkpoint inhibitors, both in monotherapy and in combination with chemotherapy or targeted therapy, across various subtypes and stages of NSCLC are fueling this expansion.

Online pharmacies are projected to be the most rapidly growing distribution channel. The growth is fueled by increasing convenience, accessibility, and sometimes cost-effectiveness provided by online channels. Increased adoption of telemedicine and remote care services also enhances the growth of online pharmacies for oral NSCLC medication distribution.

Adenocarcinoma accounted for the largest market share as it is the world's most prevalent histological subtype of NSCLC and often presents with certain genetic mutations that are targetable with therapies presently available. Its larger prevalence and available targeted therapies have helped it become a leading player in the therapeutics market.

Non-Small Cell Lung Cancer Therapeutics Market- Segmentation Analysis:

The Global Non-Small Cell Lung Cancer Therapeutics Market is segmented on the basis of Therapy, Distribution Channel, Cancer Type, and Region.

By therapy, the market is segmented into targeted therapy, immunotherapy, and chemotherapy. Targeted therapy is the most significant share of the market. The dominance results from the vast improvement in realizing the molecular background of NSCLC, where identifying certain oncogenic drivers like EGFR, ALK, ROS1, and BRAF has become possible. The innovation and approval of successful drugs targeting these mutations have transformed the treatment model of patients carrying such changes, especially in adenocarcinoma. Targeted agents commonly demonstrate greater efficacy and better toxicity profiles than conventional chemotherapy in these particular patient groups and, hence, are a key element of initial and follow-up treatment protocols. Immunotherapy is the quickest-growing segment of the market. This fast growth is driven by the game-changing effect of immune checkpoint inhibitors, which have proven the capability to yield sustained responses and long-term survival in a proportion of patients with a range of NSCLC subtypes. Broadening immunotherapy indications to the earlier stages of the disease and combined with other modalities, such as chemotherapy and targeted therapy is further propelling market growth.

Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Hospital pharmacies are the biggest segment of the market. This segment has the greatest market share because of the type of treatment for NSCLC, which frequently includes the delivery of complicated intravenous therapy like chemotherapy and most immunotherapies. Hospitals have the required infrastructure, such as specialized infusion centers and skilled healthcare professionals, to deliver and monitor these treatments safely. In addition, hospital pharmacies are most often the initial dispensing point for drugs prescribed during an inpatient stay and for outpatients treated in specialized cancer centers. Online pharmacies are the most rapidly expanding sector in the market. The rise in take-up of e-commerce and the growing convenience provided by online websites are the reasons behind this expansion. Online drugstores give patients convenient access to oral drugs employed in treating NSCLC, including targeted treatments and certain supportive care medicines. They tend to have competitive prices and home delivery convenience, which can prove especially helpful for patients with ongoing conditions like lung cancer.

Non-Small Cell Lung Cancer Therapeutics Market- Geographical Insights

North America is the largest regional market for non-small cell lung cancer medicines. This is due to several factors, such as well-established healthcare infrastructure, high healthcare spending, and major pharmaceutical firms pushing innovation and early adoption of new medicines. The US has one of the highest rates of lung cancer and an effective regulatory infrastructure that allows for quick approval & adoption of new drugs. Furthermore, the strong focus on research and development, as well as positive reimbursement policies, adds to the leadership of North America. The Asia-Pacific region has the fastest growth for non-small cell lung cancer drugs. This rapid growth is largely the result of the huge and increasing patient base in markets such as China and India, the growing incidence of smoking and air pollution, and enhancing accessibility and affordability of healthcare. The ever-increasing rate of expenditure on healthcare infrastructure and the increasing rate of utilization of advanced cancer therapies such as immunotherapy & targeted therapy are also major growth drivers. Further, the rising number of clinical trials & development of local pharma industries are pushing the region's rapid growth.

Non-Small Cell Lung Cancer Therapeutics Market- Competitive Landscape:

The market for non-small cell lung cancer therapeutics is a highly competitive one with many entrenched pharma and biotech firms, as well as new entrants. Major players like Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, AstraZeneca, Pfizer Inc., Bristol Myers Squibb, and Merck Sharp & Dohme Corp. command large market shares fueled by the broad portfolios of approved treatments, research and development strengths, and established global distribution channels. These companies are developing new targeted therapies, immunotherapies, and combination regimens to address the evolving needs of NSCLC patients and overcome resistance to treatments. Strategic collaborations, licensing agreements, and buyouts also increased the competitive intensity to expand product pipelines and market coverage. Innovation is an area of differentiator, where firms are targeting the identification of new targets of therapy, next-generation inhibitors, and novel treatment approaches such as antibody-drug conjugates and cell therapies. The rising focus on personalized medicine and biomarker-based treatment approaches also generates competition, with firms investing in companion diagnostics to determine patient subsets most likely to respond to their therapies.

Recent Developments:

December 2024: AstraZeneca and Daiichi Sankyo reported that they had submitted a new biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of datopotamab deruxtecan (Dato-DXd) as a therapy for non-small cell lung cancer (NSCLC). The application is in adult patients previously treated with unresectable or metastatic NSCLC non-squamous.

October 2023: Eli Lilly and Company announced FDA approval of selpercatinib (Retevmo) in adult patients with a rearranged during transfection4 (RET) fusion-positive tumor detected by an FDA-approved test in locally advanced or metastatic non-small cell lung cancer. This approval adds to the treatment options for this molecular subtype of NSCLC, providing a targeted therapy with proven effectiveness.

June 2023: Bristol Myers Squibb reported on the FDA approval of Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as neoadjuvant therapy followed by adjuvant monotherapy for nivolumab alone in adult patients with resectable (>=4 cm or node-positive) non-small cell lung cancer. This allows an additional dose of immunotherapy-based therapy in the perioperative setting for patients with more advanced resectable disease.

May 2023: Astellas collaborated with a biotech firm to discover and develop new antibody-drug conjugates targeting multiple cancers, including NSCLC. The collaboration will combine Astellas' expertise in antibody engineering with the partner's proprietary payload technology to develop more effective and targeted treatments for lung cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc. (Takeda)
  • Merck Sharp & Dohme Corp.

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY - MARKET ANALYSIS, 2019 - 2032

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL - MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE - MARKET ANALYSIS, 2019 - 2032

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma

GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Non-Small Cell Lung Cancer Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Therapy
    • 2.1.2. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Distribution Channel
    • 2.1.3. Non-Small Cell Lung Cancer Therapeutics Market Snippet By Cancer Type
    • 2.1.4. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Country
    • 2.1.5. Non-Small Cell Lung Cancer Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Non-Small Cell Lung Cancer Therapeutics Key Market Trends

  • 3.1. Non-Small Cell Lung Cancer Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Non-Small Cell Lung Cancer Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Non-Small Cell Lung Cancer Therapeutics Market Opportunities
  • 3.4. Non-Small Cell Lung Cancer Therapeutics Market Future Trends

4. Non-Small Cell Lung Cancer Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Non-Small Cell Lung Cancer Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Non-Small Cell Lung Cancer Therapeutics Market Landscape

  • 6.1. Non-Small Cell Lung Cancer Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Non-Small Cell Lung Cancer Therapeutics Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2024 & 2032 (%)
    • 7.1.2. Targeted Therapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Chemotherapy

8. Non-Small Cell Lung Cancer Therapeutics Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Non-Small Cell Lung Cancer Therapeutics Market - By Cancer Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Cancer Type, 2024 & 2032 (%)
    • 9.1.2. Adenocarcinoma
    • 9.1.3. Squamous Cell Carcinoma
    • 9.1.4. Large Cell Carcinoma

10. Non-Small Cell Lung Cancer Therapeutics Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Non-Small Cell Lung Cancer Therapeutics Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Cancer Type, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Non-Small Cell Lung Cancer Therapeutics Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.2.2. Eli Lilly and Company
    • 11.2.3. Celgene Corporation
    • 11.2.4. AstraZeneca
    • 11.2.5. Pfizer Inc.
    • 11.2.6. Sanofi
    • 11.2.7. Novartis AG
    • 11.2.8. Astellas
    • 11.2.9. Bristol Myers Squibb
    • 11.2.10. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 11.2.11. Millennium Pharmaceuticals, Inc. (Takeda)
    • 11.2.12. Merck Sharp & Dohme Corp.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us